WASHINGTON - The American Pharmaceutical Association awarded Mount Olive, NJ-based Knoll Pharmaceutical Co. the 15th annual H.A.B. Dunning Award.
WASHINGTON - The American Pharmaceutical Association awarded Mount Olive, NJ-based Knoll Pharmaceutical Co. the 15th annual H.A.B. Dunning Award.
The award, which recognizes exemplary contributions to the practice of pharmacy by a pharmaceutical manufacturer or provider of support products and services, will be presented during the association's 145th annual meeting and exposition in Miami Beach, FL, in March.
Knoll was nominated by the Texas Pharmacy Association for its support of educational consumer awareness and independent business programs. The association also benefited from Knoll's funding of expanded educational facilities, which allowed the association to increase its capacity by one-third. In addition, Knoll sponsored a family night for pharmacists and their families to encourage networking; an appreciation banquet for pharmacists; and a county art auction that benefited the surrounding communities.
"In each contribution, Knoll's people are with us every step of the way - evaluating the programs, looking for ways to make them better and encouraging other organizations to support our pharmacists," wrote Luther Parker, association president, and Paul Davis, association executive director, in explanation of the nomination. "We believe Knoll deserves this award not only because of the numerous contributions the company made in 1997, but also because of Knoll's history of support, and its future commitment to the practice of pharmacy." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.